Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/pin.13506 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Case of Small-Cell Lung Cancer With Novel Anaplastic Lymphoma Kinase Gene Rearrangement That Developed Intradural Extramedullary Spinal Metastases With Myelitis.
Cureus
December 2024
Department of Neurology, International University of Health and Welfare Narita Hospital, Narita, JPN.
( gene rearrangement-positive small-cell lung cancer (SCLC) is extremely rare. A 73-year-old man was diagnosed with SCLC. Standard treatments were not effective.
View Article and Find Full Text PDFALK-positive large B-cell lymphoma: A study of six cases from an oncopathology center in North India.
Indian J Pathol Microbiol
January 2025
Department of Oncopathology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, India.
ALK-positive large B-cell lymphoma (ALK+ LBCL) is a rare neoplasm with an aggressive course and poor therapeutic response to the standard R-CHOP regimen. Owing to its negativity for usual B- and T-cell markers and immunopositivity for epithelial markers, it can be easily misdiagnosed if it is not contemplated. To study the clinicopathological parameters of cases of ALK+ LBCL diagnosed at our institution.
View Article and Find Full Text PDFTwo rare ALK fusion variants overlooked by multiplexed gene testing: The crucial role of immunohistochemistry in ensuring comprehensive molecular testing.
Pathol Int
January 2025
Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Analytical performance of OncoPrism-HNSCC, an RNA-based assay to inform immune checkpoint inhibitor treatment decisions for recurrent/metastatic head and neck squamous cell carcinoma.
BMC Cancer
January 2025
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Background: While immune checkpoint inhibitor (ICI) therapies can significantly improve outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC), only about 15-20% benefit from such treatments. Clinical tests that guide the use of ICIs are therefore critically needed. OncoPrism-HNSCC was developed to address this need.
View Article and Find Full Text PDF[Intracranial mesenchymal tumors with FET::CREB fusion: a clinicopathological analysis of six cases].
Zhonghua Bing Li Xue Za Zhi
January 2025
Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou450052, China.
To investigate the clinicopathological and molecular genetic characteristics of intracranial mesenchymal tumors with FET::CREB fusion transcript. The clinical and imaging data of 6 cases of intracranial mesenchymal tumors with FET::CREB fusion from December 2018 to December 2023 were collected at the First Affiliated Hospital of Zhengzhou University. Their histological features, immunophenotype and molecular characteristics were analyzed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!